Who are ULO's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Uritos®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ulo.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

ULO — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ULO (ULO) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Uricosuric agent; URAT1 inhibitor. Area: Rheumatology; Gout.

marketed Uricosuric agent; URAT1 inhibitor URAT1 (urate transporter 1) Rheumatology; Gout Small molecule Live · refreshed every 30 min

Target snapshot

ULO (ULO) — Merck Sharp & Dohme LLC. ULO is a uricosuric agent that increases urinary excretion of uric acid by inhibiting renal urate reabsorption.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ULO TARGET	ULO	Merck Sharp & Dohme LLC	marketed	Uricosuric agent; URAT1 inhibitor	URAT1 (urate transporter 1)
Uritos®	Uritos®	R-Pharm	phase 3	Uricosuric agent / URAT1 inhibitor	URAT1 (urate transporter 1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Uricosuric agent; URAT1 inhibitor class)

Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ULO — Competitive Intelligence Brief. https://druglandscape.com/ci/ulo. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing